Efficacy and safety of arbidol (umifenovir) in patients with COVID ‐19: A systematic review and meta‐analysis

ConclusionThe present meta-analysis showed no significant benefit of using arbidol compared with non-antiviral treatment or other therapeutic agents against COVID-19 disease. High-quality studies are needed to establish the efficacy and safety of arbidol for COVID-19.

Source: Immunity, Inflammation and Disease - August 4, 2021 Category: Allergy & Immunology Authors: Behnam Amani, Bahman Amani, Sara Zareei, Mahsa Zareei Tags: REVIEW ARTICLE Source Type: research